May 2 (Reuters) - Cardinal Health raised its annual profit forecast on Thursday, betting on strength in its pharmaceutical unit selling costly specialty drugs used to treat complex conditions such as cancer. Drug distributors, including rival Cencora, have been benefiting from growing sales of specialty medicines at a time when prices of generic, or copycat, versions have been falling due to intense competition. Cardinal now expects 2024 adjusted earnings in the range of $7.30 to $7.40 per share, compared with $7.20 to $7.35 per share forecast previously. According to LSEG data, analysts were expecting an annual profit of $7.28 per share. The company also announced its preliminary outlook for 2025 adjusted profit, expecting at least $7.50 per share, compared with estimates of $7.87. Cardinal sources a substantial amount of its revenue from the pharmaceutical and specialty solutions unit through which it distributes branded and generic drugs, specialty medicines and over-the-counter healthcare and consumer products. The unit generated revenues of $50.7 billion, up 9% year-over-year, in the third quarter ended March 31. Total sales came in at $54.91 billion, missing analysts' estimates of $56.06 billion. Cardinal Health said last month its contracts with UnitedHealth Group's OptumRx, one of its largest customers, will not be renewed after they expire at the end of June. The Optum contracts, signed in 2015, contributed 16% of Cardinal's total revenue in fiscal year 2023, but the bulk of the shipments mainly comprised non-specialty medicines, according to the company. On an adjusted basis, Cardinal Health reported a profit of $2.08 per share, beating expectations of $1.95 per share. (Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath)
Cardinal Health lifts 2024 profit view on demand for costly specialty drugs
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...